[
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-1",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#definitiongeneral318862",
    "clean_content": "Definition / general\n\n* Includes well differentiated neuroendocrine tumors (WDNET) and poorly differentiated neuroendocrine carcinomas (PDNEC)* Express neuroendocrine markers (synaptophysin and chromogranin A) (see [Positive stains](https://www.pathologyoutlines.com/topic/pancreaspen.html#positivestains))* Mixed neuroendocrine nonneuroendocrine neoplasms (MiNEN) includes both neuroendocrine and nonneuroendocrine component (e.g., adenocarcinoma, acinar carcinoma), each ≥ 30%* Functional tumors are associated with elevated serum hormone levels and a clinical hormonal syndrome (see [Clinical features](https://www.pathologyoutlines.com/topic/pancreaspen.html#clinicalfeatures))* Nonfunctional tumors are more common and are not associated with a clinical hormonal syndrome\n          + May still be associated with elevated serum hormone levels or tissue hormone expression on immunohistochemistry+ Nonfunctional tumors < 0.5 cm are termed pancreatic neuroendocrine microadenomas"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-2",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#essentialfeatures318863",
    "clean_content": "Essential features\n\n* Well differentiated neuroendocrine tumors (WDNET):\n  + Clumped chromatin (salt and pepper) nuclei+ Cellular uniformity, central ovoid nucleus+ Organoid architecture: ribbons / trabeculae, nesting, glandular, gyriform, pseudoacinar+ Necrosis is rare+ Amyloid deposition in insulinomas+ Psammoma bodies in somatostatinomas (also associated with NF1)+ Background of microadenomas in multiple endocrine neoplasia type 1 (MEN1) and von Hippel-Lindau (VHL) syndromes+ Clear cell morphology in von Hippel-Lindau syndrome* Poorly differentiated neuroendocrine carcinomas (PDNEC):\n    + Diffuse sheets or solid nests of markedly atypical malignant cells with small cell or large cell morphology+ Abundant mitoses and apoptotic bodies+ Necrosis is frequent"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-3",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#terminology318864",
    "clean_content": "Terminology\n\n* Antiquated terms: islet cell tumor / carcinoma, carcinoid, APUDoma* Classification based on WHO system:\n    + Per WHO 2019, neuroendocrine neoplasms with Ki67 > 20% are now regarded in 2 distinct groups, WDNET grade 3 or PDNEC, based on the morphologic characteristics\n      + Well differentiated neuroendocrine tumor grading:\n        - WHO grade 1: < 2 mitoses/2 mm2 or Ki67 index < 3%- WHO grade 2: 2 - 20 mitoses/2 mm2 or Ki67 index 3 - 20%- WHO grade 3: > 20 mitoses/2 mm2 or Ki67 > 20%+ Ki67 count should be done on a minimum of 500 cells in hot spot areas+ Both mitotic count and Ki67 should be performed and grade is assigned based on largest value; usually Ki67 is higher than mitotic count ([Am J Surg Pathol 2013;37:1671](24121170))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-4",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#epidemiology318865",
    "clean_content": "Epidemiology\n\n* 1 - 5% of all pancreatic neoplasms; increasing incidence due to improved imaging techniques ([Arch Pathol Lab Med 2019;143:1317](31509453), [Cancer 2015;121:589](25312765))* Incidence of 1 per 100,000 persons ([Cancer 2015;121:589](25312765))* Wide age range but most common in third to sixth decades ([Arch Pathol Lab Med 2019;143:1317](31509453))* M = F ([Arch Pathol Lab Med 2019;143:1317](31509453))* Most are sporadic* 10 - 20% associated with syndrome ([Arch Pathol Lab Med 2019;143:1317](31509453)):\n            + 20 - 70% of multiple endocrine neoplasia 1 (MEN1) patients+ 20% von Hippel-Lindau (VHL) patients+ 10% neurofibromatosis type 1 (NF1) patients+ 1% of tuberous sclerosis complex (TSC) patients"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-5",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#sites318866",
    "clean_content": "Sites\n\n* WDNET is more common in tail and body ([Arch Pathol Lab Med 2019;143:1317](31509453))* PDNEC is more common in head ([Arch Pathol Lab Med 2019;143:1317](31509453))* See [Clinical hormonal syndromes](https://www.pathologyoutlines.com/topic/pancreaspen.html#clinicalhormonal)"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-6",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#pathophysiology318867",
    "clean_content": "Pathophysiology\n\n* Varies with clinical syndrome (see [Clinical features](https://www.pathologyoutlines.com/topic/pancreaspen.html#clinicalfeatures))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-7",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#etiology318868",
    "clean_content": "Etiology\n\n* Risk factors include smoking, diabetes and first degree relative with history of cancer ([Sci Rep 2016;6:36073](27782199))* Subset associated with MEN1 (*MEN1* gene on 11q13), von Hippel-Lindau (*VHL* tumor suppressor gene on 3p25), neurofibromatosis 1 (microdeletion in neurofibromin gene on 17q11.2) and tuberous sclerosis complex (*TSC1* tumor suppressor gene on 9q34 or *TSC2* tumor suppressor gene on 16p13.3) ([Arch Pathol Lab Med 2019;143:1317](31509453))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-8",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#clinicalfeatures318869",
    "clean_content": "Clinical features\n\n* Nonfunctional tumors are encountered incidentally and are usually larger at time of diagnosis* Local obstruction / mass effect, if located in the pancreatic head* Other clinical features of MEN1, VHL, NF1 or TSC (if applicable)\n      * Clinical hormonal syndromes in functioning tumors, 10 - 30% of tumors ([Arch Pathol Lab Med 2009;133:350](19260741))\n\n* Insulinoma:\n  + Most common+ Insulin secretion+ Whipple triad: symptoms of hypoglycemia, low plasma glucose, relief of symptoms with glucose administration+ Solitary tumor < 2 cm+ 5 - 10% MEN1 and are usually multiple+ Generally indolent* Gastrinoma:\n    + Second most common functioning pancreatic neuroendocrine tumor+ Gastrin secretion+ Zollinger-Ellison syndrome (peptic / duodenal ulcers, gastroesophageal reflux, diarrhea)+ Located in gastrinoma triangle (common bile duct, duodenum, pancreatic head)+ More commonly found in duodenum than pancreas+ 20 - 30% associated with MEN1* Glucagonoma:\n      + 4 Ds: diabetes, dermatitis (necrolytic migratory erythema), deep vein thrombosis, depression+ Solitary, large+ Tail > head+ > 50% have metastasis at presentation* VIPoma:\n        + Verner-Morrison syndrome: watery diarrhea, hypokalemia, achlorhydria / hypochlorhydria+ Solitary, large+ Tail > head* Somatostatinoma:\n          + Diabetes mellitus, diarrhea or steatorrhea, anemia, malabsorption, cholelithiasis+ Very rare+ Solitary, large+ > 50% have metastasis at presentation* Ectopic hormone producing neuroendocrine tumor:\n            + ACTH (Cushing syndrome), serotonin (atypical carcinoid syndrome), growth hormone+ Solitary, large"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-9",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#laboratory318870",
    "clean_content": "Laboratory\n\n* Elevated serum hormone in functional tumors (see [Clinical features](https://www.pathologyoutlines.com/topic/pancreaspen.html#clinicalfeatures))* Elevated serum chromogranin A in 50 - 100%; correlates with tumor burden and metastasis but has limited utility due to low specificity and sensitivity ([Arch Pathol Lab Med 2019;143:1317](31509453))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-10",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#radiologydescription318871",
    "clean_content": "Radiology description\n\n* Round, solid, hypervascular* Subset may be cystic* Well circumscribed* Contrast enhanced computed tomography (CT) has decreased sensitivity in smaller (< 2 cm) tumors ([Clin Endosc 2017;50:537](29207856))* Magnetic resonance imaging (MRI) has better sensitivity, especially for small tumors compared with CT ([Clin Endosc 2017;50:537](29207856))* Gallium 68 dotatate positron emission tomography (PET) ([Clin Endosc 2017;50:537](29207856)):\n            + Uses radiolabeled somatostatin analog+ Useful for WDNETs, most of which express somatostatin receptor+ High sensitivity and specificity for somatostatin receptor expressing tumors"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-11",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#radiologyimages318872",
    "clean_content": "Radiology images\n\nImages hosted on other servers:  \n\n[![](https://www.pathologyoutlines.com/thumb/pancreaspenradio1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430610/figure/ijerph-18-08895-f004/)\n\nMRI demonstrating small WDNET\n\n[![](https://www.pathologyoutlines.com/thumb/pancreaspenradio2.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430610/figure/ijerph-18-08895-f005/)\n\nCT and Gallium 68 Dotatate PET showing WDNET"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-12",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#prognosticfactors318873",
    "clean_content": "Prognostic factors\n\n* WDNETs are usually slow growing with prolonged clinical course* PDNECs are usually aggressive and rapidly progressive* Ki67 index and mitotic count, as described for WHO grading* Prognostic immunohistochemical markers (not widely used in routine clinical practice):\n        + Expression of COX2, p27, CD99 and PR immunostains ([Pathol Int 2001;51:770](11881729), [Am J Clin Pathol 2003;120:685](14608893), [Am J Surg Pathol 2006;30:1588](17122516), [Cancer 1992;70:2268](1356613))+ Expression of CK19 is associated with aggressive behavior ([Am J Surg Pathol 2006;30:1588](17122516), [Histopathology 2007;50:597](17394496), [Am J Surg Pathol 2004;28:1145](15316313))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-13",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#casereports318874",
    "clean_content": "Case reports\n\n* 45 year old woman with possible VHL syndrome with mixed serous neuroendocrine neoplasm ([World J Clin Cases 2019;7:4119](31832417))* 48 year old man with cystic pancreatic WDNET radiographically mimicking cystic mucinous neoplasm ([Autops Case Rep 2020;10:e2020171](33344296))* 53 year old man with pancreatic WDNET with rhabdoid features ([Virchows Arch 2018;473:247](29938394))* 58 year old woman with systemic mastocytosis incidentally found to have pancreatic WDNET ([Int J Surg Case Rep 2020;77:397](33220657))* 73 year old woman with breast carcinoma with unrecognized neuroendocrine differentiation metastasizing to the pancreas ([Int J Surg Pathol 2016;24:463](26912472))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-14",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#treatment318875",
    "clean_content": "Treatment\n\n* Surgical resection is the mainstay for WDNET, with resolution of both mass effect symptoms and symptoms associated with hormone secretion ([Surg Clin North Am 2019;99:793](31255207))\n  + Benefit for both localized and metastatic disease* Other therapies for metastatic WDNET ([Surg Clin North Am 2019;99:793](31255207)):\n    + Somatostatin analog therapy+ Molecular therapies: tyrosine kinase inhibitor, sunitinib; mTOR inhibitor, everolimus+ Chemotherapy (capecitabine and temozolomide [CAPTEM])+ Peptide receptor radionuclide therapy (PRRT)+ Liver directed therapy: ablation or hepatic artery embolization of liver metastasis* PDNECs usually treated with platinum based chemotherapy ([Surg Clin North Am 2019;99:793](31255207))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-15",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#grossdescription318876",
    "clean_content": "Gross description\n\n* Usually well circumscribed, homogeneous* May have cystic change* Color and consistency varies according to degree of vascularity and stroma, ranges from white to pink to tan to brown; may be yellow if necrosis present ([Arch Pathol Lab Med 2009;133:350](19260741))* Pigmented black pancreatic neuroendocrine tumor contains intracytoplasmic lipfuscin and mimics metastatic melanoma ([Arch Pathol Lab Med 2009;133:350](19260741))* Lipid rich pancreatic neuroendocrine tumor appears yellow and may mimic adrenal cortical neoplasia ([Arch Pathol Lab Med 2009;133:350](19260741))* Large tumors may appear lobulated and infiltrative* Can invade adjacent fibroadipose tissue, other organs and large vessels"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-16",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#grossimages318877",
    "clean_content": "Gross images\n\nContributed by Danielle Hutchings, M.D.  \n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings01.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings01.jpg)\n\nWell circumscribed, solid tumor in pancreatic tail\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings02.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings02.jpg)\n\nTumor with hemorrhage\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings03.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings03.jpg)\n\nInvasion into spleen\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings04.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings04.jpg)\n\nLarge vessel invasion\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings05.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings05.jpg)\n\nPancreatic duct obstruction\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings06.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings06.jpg)\n\nCystic degeneration"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-17",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#microscopichistologicdescription318878",
    "clean_content": "Microscopic (histologic) description\n\n* Well differentiated neuroendocrine tumors:\n  + Organoid architecture: solid nests, trabeculae, gyri, cords, festoons, ribbons, glandular, tubuloacinar+ Small to medium cells with eosinophilic to amphophilic and finely granular cytoplasm; nuclei are uniform, central, round / oval, with salt and pepper (finely stippled) chromatin; no or inconspicuous nucleoli+ Rich vascular network+ Amyloid deposition in insulinomas+ Psammoma bodies in somatostatinomas+ May have hyaline globules ([Am J Surg Pathol 2011;35:981](21677537))+ Variants include clear cell, lipid rich, oncocytic, rhabdoid and pigmented black neuroendocrine neoplasm ([Arch Pathol Lab Med 2019;143:1317](31509453), [Virchows Arch 2018;473:247](29938394), [Cancer 2001;92:1984](11745274))* Poorly differentiated neuroendocrine carcinomas:\n    + Diffuse sheets or solid nests of markedly atypical malignant cells+ Salt and pepper chromatin is lost+ Abundant mitoses and apoptotic bodies+ Necrosis is frequent+ May be small cell (high N/C ratio, nuclear hyperchromasia and molding) or large cell (moderate to abundant amphophilic cytoplasm, may have prominent nucleoli) morphology"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-18",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#microscopichistologicimages318879",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Danielle Hutchings, M.D. and Sabrina Sopha, M.D.  \n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings07.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings07.jpg)\n\nAmyloid deposition\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings08.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings08.jpg)\n \n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings09.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings09.jpg)\n\nPoorly differentiated neuroendocrine carcinoma, small cell type\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings10.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings10.jpg)\n\nPoorly differentiated   \nneuroendocrine   \ncarcinoma, large   \ncell type\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings12.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings12.jpg)\n\nCalcification\n\n  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha01new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha01new.jpg)\n\nCribriform pattern\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha14new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha14new.jpg)\n\nPseudoacinar pattern\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha15new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha15new.jpg)\n\nOrganoid pattern\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha13new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha13new.jpg)\n\nKi67 staining\n\n[![](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings11.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenHutchings11.jpg)\n\nINSM1 immunostain\n\n  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha03new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha03new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha04new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha04new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha05new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha05new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha06new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha06new.jpg)\n\nSpread to duodenum (H&E and synaptophysin)\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha07new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha07new.jpg)\n\nSynaptophysin staining\n\n  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha08new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha08new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha09new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha09new.jpg)\n\nSynaptophysin staining\n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha10new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha10new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha11new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha11new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha12new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha12new.jpg)\n\nChromogranin staining\n\n  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha19new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha19new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha20new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha20new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha21new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha21new.jpg)\n\nWell differentiated pancreatic neuroendocrine tumor  \n (cell block, synaptophysin, chromogranin)"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-19",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#cytologydescription318880",
    "clean_content": "Cytology description\n\n* Well differentiated neuroendocrine tumors ([Diagn Cytopathol 2006;34:649](16900463)):\n  + Cellular specimen with clean background+ Clusters and individual cells+ Uniform round oval, small / medium sized cells+ Frequently plasmacytoid+ Amphophilic, finely granular cytoplasm (neurosecretory capability)* Poorly differentiated neuroendocrine carcinomas ([Diagn Cytopathol 2006;34:649](16900463)):\n    + Overtly malignant cells with small cell or large cell morphology+ Necrosis"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-20",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#cytologyimages318881",
    "clean_content": "Cytology images\n\nContributed by Sabrina Sopha, M.D. and AFIP images  \n\n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha16new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha16new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha17new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha17new.jpg)\n \n[![Missing Image](https://www.pathologyoutlines.com/imgau/pancreaspenSopha18new.jpg)](https://www.pathologyoutlines.com/imgau/pancreaspenSopha18new.jpg)\n\nWell differentiated pancreatic neuroendocrine tumor  \n (pap stained smears)\n\n[![Missing Image](https://www.pathologyoutlines.com/images/pancreas/9_04.jpg)](https://www.pathologyoutlines.com/images/pancreas/9_04.jpg )\n\nRound nuclei and scanty cytoplasm"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-21",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#positivestains318882",
    "clean_content": "Positive stains\n\n* Epithelial markers: [CK8](https://www.pathologyoutlines.com/topic/stainsck8.html) / [CK18](https://www.pathologyoutlines.com/topic/stainsck18.html), [CAM 5.2](https://www.pathologyoutlines.com/topic/stainscam52.html), [OSCAR](https://www.pathologyoutlines.com/topic/stainsoscarkeratin.html), [AE1 / AE3](https://www.pathologyoutlines.com/topic/stainsae1ae3.html) (labels 50% of tumors) ([Virchows Arch A Pathol Anat Histopathol 1986;409:609](3092460))* Neuroendocrine markers:\n    + [Synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html): strong and diffuse in WDNET; may be weak, patchy or negative in PDNEC ([Hum Pathol 2020;96:8](31857137))+ [Chromogranin A](https://www.pathologyoutlines.com/topic/stainschromogranin.html): may be more focal and 10 - 20% of WDNET may be negative; may be focal or negative in PDNEC ([Hum Pathol 2020;96:8](31857137))+ [INSM1](https://www.pathologyoutlines.com/topic/stainsinsm1.html): newer marker with high sensitivity and specificity ([Am J Clin Pathol 2015;144:579](26386079))+ [CD56](https://www.pathologyoutlines.com/topic/cdmarkerscd56.html), [neuron specific enolase (NSE)](https://www.pathologyoutlines.com/topic/stainsnse.html), [CD57](https://www.pathologyoutlines.com/topic/cdmarkerscd57.html): less specific, limited utility ([Hum Pathol 2020;96:8](31857137))* Panel to determine pancreatic origin for WDNET: **Islet1**+, **PAX6**+, [TTF1](https://www.pathologyoutlines.com/topic/stainsttf1.html)-, [CDX2](https://www.pathologyoutlines.com/topic/stainscdx2.html) usually negative, [SATB2](https://www.pathologyoutlines.com/topic/stainsSATB2.html)-\n      + Panel is nonspecific in the setting of PDNEC+ [TTF1](https://www.pathologyoutlines.com/topic/stainsttf1.html) is positive in 40% of extrapulmonary PDNEC ([Hum Pathol 2020;96:8](31857137))* Panel to differentiate WDNET, grade 3 from PDNEC ([Arch Pathol Lab Med 2019;143:1317](31509453))\n        + WDNET: somatostatin receptor+, loss of [DAXX / ATRX](https://www.pathologyoutlines.com/topic/stainsatrx.html)+ PDNEC: abnormal expression of [p53](https://www.pathologyoutlines.com/topic/stainsp53.html), loss of [RB1](https://www.pathologyoutlines.com/topic/stainsrb.html), loss of [SMAD4 / DPC4](https://www.pathologyoutlines.com/topic/stainsdpc4.html)* Hormone expression (**insulin**, **glucagon**, [gastrin](https://www.pathologyoutlines.com/topic/stainsgastrin.html), [somatostatin](https://www.pathologyoutlines.com/topic/stainssomatostatin.html), **VIP**, **pancreatic polypeptide**): may be seen but does not indicate functional tumor* [Trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html): scattered positive cells may be seen but if > 25%, the tumor is classified as mixed ([Am J Surg Pathol 1994;18:765](8037290), [Am J Surg Pathol 2002;26:893](12131156), [Dig Dis Sci 2002;47:2254](12395898))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-22",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#negativestains318883",
    "clean_content": "Negative stains\n\n* [Beta catenin](https://www.pathologyoutlines.com/topic/stainsbetacatenin.html) (labels cell membrane only) ([Arch Pathol Lab Med 2019;143:1317](31509453))* [Trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html) (negative or only few positive cells) ([Am J Surg Pathol 1994;18:765](8037290), [Am J Surg Pathol 2002;26:893](12131156), [Dig Dis Sci 2002;47:2254](12395898))* **Chymotrypsin** ([Arch Pathol Lab Med 2019;143:1317](31509453))* [BCL10](https://www.pathologyoutlines.com/topic/stainsbcl10.html) ([Arch Pathol Lab Med 2019;143:1317](31509453))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-23",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Electron microscopy images",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#electronmicroscopyimages318884",
    "clean_content": "Electron microscopy images\n\nAFIP images  \n\n[![Missing Image](https://www.pathologyoutlines.com/images/pancreas/5_40C.jpg)](https://www.pathologyoutlines.com/images/pancreas/5_40C.jpg)\n\nEnterochromaffin cell tumor: irregularly shaped"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-24",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#molecularcytogeneticsdescription318885",
    "clean_content": "Molecular / cytogenetics description\n\n* WDNETs:\n  + *MEN1* inactivation 44% ([Arch Pathol Lab Med 2019;143:1317](31509453))+ *DAXX / ATRX* mutation or loss 43% ([Arch Pathol Lab Med 2019;143:1317](31509453))+ mTOR pathway alterations (*PTEN, TSC2, PIK3CA*) 14% ([Arch Pathol Lab Med 2019;143:1317](31509453))+ *VHL* small subset ([Semin Diagn Pathol 2014;31:498](25441311))* Poorly differentiated neuroendocrine carcinomas and mixed neuroendocrine nonneuroendocrine neoplasms:\n    + *TP53*, *RB*, *KRAS*, *APC*, *BRAF*, *SMAD4 / DPC4* (more like adenocarcinomas) ([Arch Pathol Lab Med 2019;143:1317](31509453), [Am J Surg Pathol 2012;36:173](22251937))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-25",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Videos",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#videos318886",
    "clean_content": "Videos\n\nSolid tumors of the pancreas"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-26",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#samplepathologyreport318887",
    "clean_content": "Sample pathology report\n\n* Pancreas, distal pancreatectomy:\n  + Well differentiated neuroendocrine tumor, WHO grade 1 of 3 (3 cm) (see comment)\n    - Ki67 proliferation index: 2%- 1 mitosis per 2 mm2- Tumor confined to the pancreas+ Lymphovascular and perineural invasion identified+ Proximal pancreatic parenchyma margin is uninvolved+ Metastatic tumor in 2/17 lymph nodes+ Comment: The tumor cells are positive for synaptophysin and chromogranin A."
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-27",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#differentialdiagnosis318888",
    "clean_content": "Differential diagnosis\n\n* **Solid pancreatic tumors**:\n  + [Acinar cell carcinoma](https://www.pathologyoutlines.com/topic/pancreasacinar.html):\n    - Adults, high mitotic rate, labeling with [BCL10](https://www.pathologyoutlines.com/topic/stainsbcl10.html), [trypsin](https://www.pathologyoutlines.com/topic/stainstrypsin.html), **chymotrypsin**- May have focal positivity with [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) but [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html) is negative+ [Pancreatoblastoma](https://www.pathologyoutlines.com/topic/pancreaspancreatoblastoma.html):\n      - Children, squamoid nests+ [Solid pseudopapillary neoplasm](https://www.pathologyoutlines.com/topic/pancreassolidpseudo.html):\n        - Women, degenerated pseudopapillae, hyaline globules- Nuclear labeling with [beta catenin](https://www.pathologyoutlines.com/topic/stainsbetacatenin.html)- May have focal positivity with [synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) but [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html) is negative+ [Usual ductal adenocarcinoma](https://www.pathologyoutlines.com/topic/pancreasductal.html):\n          - Desmoplastic stroma- Invasive mucin producing glands+ [Paraganglioma](https://www.pathologyoutlines.com/topic/adrenalparaganglioma.html):\n            - Very rare, nested zellballlen architecture- [Cytokeratin](https://www.pathologyoutlines.com/topic/stainsckgeneral.html) negative, [S100](https://www.pathologyoutlines.com/topic/stainss100.html) highlights sustentacular cells, [GATA3](https://www.pathologyoutlines.com/topic/stainsgata3.html) positive ([Mod Pathol 2013;26:1365](23599157))* **Clear cell tumors**:\n    + [Clear cell sarcoma](https://www.pathologyoutlines.com/topic/softtissueclearcellsarcoma.html):\n      - Labels with **melanoma markers** and has t(12;22)+ [Metastatic renal cell carcinoma](https://www.pathologyoutlines.com/topic/kidneytumormalignantrcc.html):\n        - [PAX8](https://www.pathologyoutlines.com/topic/stainspax8.html)++ [PEComa](https://www.pathologyoutlines.com/topic/uterusPEComa.html):\n          - Labels with **melanoma markers**, [inhibin](https://www.pathologyoutlines.com/topic/stainsinhibina.html), [cathepsin K](https://www.pathologyoutlines.com/topic/stainscathepsink.html) and [TFE3](https://www.pathologyoutlines.com/topic/stainstfe3.html), melanoma and other clear cell tumors+ [Solid variant of serous cystadenoma](https://www.pathologyoutlines.com/topic/pancreasserous.html):\n            - Labels with [inhibin](https://www.pathologyoutlines.com/topic/stainsinhibina.html) ([Am J Surg Pathol 2004;28:339](15104296))"
  },
  {
    "id": "neuroendocrine-neoplasms-general_39076_1750166974.txt-28",
    "source_document": "neuroendocrine-neoplasms-general_39076_1750166974.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/pancreaspen.html#additionalreferences318889",
    "clean_content": "Additional references\n\n* [J Gastrointest Oncol 2020;11:548](32655934), [Histopathology 2018;72:168](29239037), [Am J Surg Pathol 2021;45:25](33177340), [Clin Cancer Res 2016;22:1011](26482044), [WHO Classification of Digestive System Tumours, 5th Edition, 2019](https://www.amazon.com/exec/obidos/ASIN/9283244990/pathologyoutl-20)"
  }
]